Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone propionate
Drug ID BADD_D02173
Description Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. It is a synthetic androstane steroid derivative of testosterone in the form of 17β propionate ester of testosterone.[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]
Indications and Usage Testosterone propionate is used in veterinary practice in heifers in order to stimulate maximal growth.[L1160]
Marketing Status approved; investigational; vet_approved; withdrawn
ATC Code Not Available
DrugBank ID DB01420
KEGG ID D00959
MeSH ID D043343
PubChem ID 5995
TTD Drug ID Not Available
NDC Product Code 62991-1412; 38779-0165; 43647-789; 64025-0019; 22552-0015; 49452-0011; 51927-1029; 48087-0134; 51927-0246; 60870-0253; 0009-5123; 30007-833; 52128-172; 51552-0030
UNII WI93Z9138A
Synonyms Testosterone Propionate | Testosteron Propionat Eifelfango | Eifelfango, Testosteron Propionat | Virormone | Agovirin
Chemical Information
Molecular Formula C22H32O3
CAS Registry Number 57-85-2
SMILES CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peliosis hepatis09.01.07.010---
Personality disorder19.05.02.002---
Polycythaemia01.07.01.001---
Priapism21.03.01.005; 24.04.12.007---
Pruritus23.03.12.001--
Rash23.03.13.001---
Rash pustular11.01.12.002; 23.03.10.003--
Seborrhoeic dermatitis23.03.04.018---
Skin disorder23.03.03.007---
Sleep apnoea syndrome17.15.05.001; 19.02.05.002; 22.02.01.013--
Testicular atrophy05.05.02.004; 21.13.01.001---
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Application site vesicles08.02.01.009; 12.07.01.009; 23.03.01.009---
Erythropoiesis abnormal01.07.02.010---
Prostatomegaly21.04.01.002---
Musculoskeletal discomfort15.03.04.001---
Free prostate-specific antigen increased13.23.01.001---
Haemorrhage24.07.01.002---
Cognitive disorder17.03.03.003; 19.21.02.001--
Precocious puberty05.05.03.001; 21.03.02.009--
Disturbance in sexual arousal19.08.04.003---
Angiopathy24.03.02.007---
Prostate cancer16.25.01.001; 21.04.02.002---
Breast disorder21.05.04.004---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Inflammation08.01.05.007; 10.02.01.089---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages